Eledon Pharmaceuticals, Inc. (ELDN)
3.02
+0.04
(+1.34%)
USD |
NASDAQ |
Sep 01, 15:42
Eledon Pharmaceuticals Cash from Operations (TTM) : -73.86M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -73.86M |
| March 31, 2026 | -68.89M |
| December 31, 2025 | -62.34M |
| September 30, 2025 | -67.24M |
| June 30, 2025 | -64.53M |
| March 31, 2025 | -54.59M |
| December 31, 2024 | -47.27M |
| September 30, 2024 | -37.42M |
| June 30, 2024 | -37.90M |
| March 31, 2024 | -38.34M |
| December 31, 2023 | -39.53M |
| September 30, 2023 | -39.88M |
| June 30, 2023 | -32.20M |
| March 31, 2023 | -30.19M |
| December 31, 2022 | -28.42M |
| September 30, 2022 | -28.15M |
| June 30, 2022 | -30.67M |
| March 31, 2022 | -31.90M |
| December 31, 2021 | -28.91M |
| September 30, 2021 | -29.14M |
| June 30, 2021 | -22.61M |
| March 31, 2021 | -18.18M |
| December 31, 2020 | -15.21M |
| September 30, 2020 | -7.802M |
| Date | Value |
|---|---|
| June 30, 2020 | -10.13M |
| March 31, 2020 | -12.03M |
| December 31, 2019 | -13.86M |
| September 30, 2019 | -15.19M |
| June 30, 2019 | -15.23M |
| March 31, 2019 | -13.64M |
| December 31, 2018 | -11.89M |
| September 30, 2018 | -11.15M |
| June 30, 2018 | -11.63M |
| March 31, 2018 | -16.33M |
| December 31, 2017 | -14.94M |
| September 30, 2017 | -13.61M |
| June 30, 2017 | -11.67M |
| March 31, 2017 | 3.935M |
| December 31, 2016 | -4.923M |
| September 30, 2016 | -12.52M |
| June 30, 2016 | -21.29M |
| March 31, 2016 | -39.87M |
| December 31, 2015 | -41.24M |
| September 30, 2015 | -38.82M |
| June 30, 2015 | -33.03M |
| March 31, 2015 | -27.45M |
| December 31, 2014 | -21.12M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.293B |
| Viking Therapeutics, Inc. | -418.44M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |